Jim Martineau

Jim co-founded Nosis after working for more than 15 years at the intersection of data science and healthcare innovation. Most recently, Jim was Head of Oncology Products at Natera (NASDAQ: NTRA) where he was responsible for the product roadmap, product definition, prioritization, technical leadership, and strategic vision for Natera’s Oncology product portfolio. Jim’s products included Signatera, the leading Molecular Residual Disease test for early relapse detection in solid tumors, as well as other NGS-related tissue and liquid biopsy profiling products and technologies. Jim’s products are actively used today by thousands of medical oncologists, by tens of thousands of patients, in dozens of clinical trials, and have been published in NEJM, Nature, and JAMA Oncology.

Prior to Natera, Jim spent four years with Flatiron Health (acquired by Roche in 2018 for $2 billion). At Flatiron, Jim served as Director of Product and Operations holding responsibility for product strategy, budgeting, roadmap, product execution, and operations. In this position, Jim concepted, built, and launched a suite of enterprise real world data products that are used today by thousands of medical oncologists, hundreds of researchers, and in partnership with multiple National Cancer Institute-Designated Academic Medical Centers of Excellence.

Jim received his MBA in Health Care Management from The Wharton School at the University of Pennsylvania. He earned his MS in Computational & Mathematical Engineering from Stanford University and his BS in Engineering Physics from the Colorado School of Mines.